No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA
Firm now plans to discuss path forward, which may include additional trials of the COX-2 inhibitor, with FDA, Novartis tells "The Pink Sheet" DAILY.
Firm now plans to discuss path forward, which may include additional trials of the COX-2 inhibitor, with FDA, Novartis tells "The Pink Sheet" DAILY.